Imaging Solid Tumors That Express PSMA With a PET Scan
Tests a PSMA-targeted PET scan in people with solid cancers that express PSMA.
Key facts
- Who runs it
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Where
- Sherbrooke, CanadaSee the site
- Trial code
- Registry title
- 68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 21 Jan 2022
- Expected to end
- 31 Jan 2027
- Type of study
- Observational
- Treatments tested
- [68Ga]-PSMA-617
- Record updated
- 7 February 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a suspected, proven or past solid tumor that makes PSMA, who have a doctor's request for a 68Ga-PSMA-617 PET/CT scan.
- Sex
- All sexes can join.
- Disease stage
- Suspected, proven or past tumor that makes PSMA. The summary says all solid cancers can be included, but not non-solid cancers.
- Earlier treatment
- No earlier severe allergic reaction to 68Ga-PSMA-617.
- Biomarker or test result
- The tumor makes PSMA.
Main reasons for not taking part
- Refusing to take part
- Earlier severe allergic (anaphylactic) reaction to 68Ga-PSMA-617
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Clinical requisition for a 68Ga-PSMA-617 PET/CT signed by a referring doctor
- Patients with suspected, proven or prior tumor expressing PSMA
- Informed consent by patient
Who cannot take part
- Prior severe anaphylactic reaction to 68Ga-PSMA-617
- Patient refusal to participate
Where in Canada
- CHUSSherbrooke, CanadaContact: Éric E Turcotte, MDTaking people
About the trial
What the trial wants to find out
This project aims to monitor the innocuity/safety profile of cyclotron-produced [68Ga]-PSMA-617 PET imaging in PSMA-expressing cancers. It is a single-site, pragmatic, non-randomized and open-label study, with no control group. Although prostate cancers constitute the usual recommended population for this PET modality, recent evidences suggest that most solid tumors express substantial amount of PSMA in their neovasculature. As such, all cancers (excluding non-solid cancers) will be eligible for [68Ga]-PSMA-617 PET imaging in this trial, for as long as their tumors express PSMA.
Read full original descriptionShow less
This study also aims to instigate the use of [68Ga]-PSMA-617 in the routine standard-of-care for detection and follow-up of eligible cancers. FInally, this project seeks to gather information about the impact on patient management this novel PET modality will have over the current standard-of-care.
The group in the trial
- Patients eligible for [68Ga]-PSMA-617-PET
All cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with a \[68Ga\]-PSMA-617 dose calculated depending on the characteristics of the PET tomograph and patient weight (maximum 370 MBq). 60-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician. Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed.
Treatment: [68Ga]-PSMA-617
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pragmatic Study on the Use of 68Ga-PSMA-617 PET/CT Imaging as a Standard of Care to Influence Clinical Management of Tumors Overexpressing PSMA.
- Plain-language title
- Imaging Solid Tumors That Express PSMA With a PET ScanGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 7 February 2024